Panel: Advancing ADCs: Precision Innovation for the Future of Targeted Therapies

Antibody-drug conjugates (ADCs) are transforming targeted therapy, offering greater precision and effectiveness in treating complex diseases. As the field evolves, innovations in linker technology, payload selection, and antibody engineering are driving the next generation of ADCs. However, challenges in stability, manufacturing, and market differentiation remain. This article explores the latest advancements shaping ADC development and how pharmaceutical companies are leveraging precision engineering to refine these powerful therapies for improved patient outcomes.